A hormone best known for promoting sleep may hold fresh promise for patients suffering from systemic lupus erythematosus (SLE), a chronic autoimmune illness that can harm several organs. A recent scientific analysis reveals that melatonin may have a larger role in reducing inflammation and oxidative stress in lupus, but experts caution that more data is needed before it can be routinely suggested. 

The review, published in Current Molecular Pharmacology, was led by researchers from Iran University of Medical Sciences and UT Health San Antonio. It focuses on melatonin, a naturally occurring molecule produced mostly by the pineal gland in the brain that helps regulate the body's sleep-wake cycle. Scientists now believe its impact extends well beyond sleep. 

Systemic lupus erythematosus develops when the immune system erroneously targets its own tissues. This can harm the skin, joints, kidneys, heart, and brain. Lupus nephritis, a disorder in which the kidneys become inflamed, has the potential to cause renal failure. Current treatments rely on immunosuppressive medicines, which can alleviate symptoms but frequently have substantial adverse effects. 

According to the review, individuals with SLE often have reduced amounts of melatonin in their blood. These lower levels appear to be associated with increased disease activity. "Our findings suggest that melatonin could serve as both a diagnostic marker and a therapeutic agent," explained co-author Azam Hosseinzadeh. 

Melatonin is renowned for its powerful antioxidant and anti-inflammatory effects. Antioxidants help neutralise dangerous molecules known as free radicals, which can damage cells and exacerbate inflammation. Studies in labs and on animals have shown that melatonin can reduce inflammation and oxidative stress in kidneys affected by lupus, suggesting it might help protect these organs. 

Early human investigations have also yielded encouraging results. A randomised, double-blind clinical experiment discovered that SLE patients who took melatonin supplements had decreased levels of malondialdehyde (MDA), a chemical marker associated with oxidative stress. However, the analysis cautions that, while these modifications appear to have a biological benefit, the overall impact on disease severity and long-term outcomes is unknown. 

The researchers suggest caution. "Melatonin's safety profile and multifaceted effects make it a compelling candidate for adjunctive therapy, but we need to understand optimal dosing and timing," said Mohammad Sheibani, a co-author. This is especially essential because melatonin levels naturally rise and decrease throughout the day and night; thus, test findings may differ depending on when samples are collected. 

The authors conclude that larger, longer-term clinical trials are necessary. Future research should look into if melatonin can help avoid organ damage, improve quality of life, and safely supplement current lupus treatments. 

Melatonin is currently an attractive yet unproven approach. The findings provide promise, but they also highlight the meticulous steps that must be taken before a well-known sleep hormone may play a new role in the complex therapy landscape of lupus.